Wall Street and investors are excited about the possibility of an acquisition after Gilead priced $10 billion in notes last week. But here's why you should be concerned.
Short-sellers make money when stocks go down, and they've latched onto these Dow Jones Industrial Average components.
Long a disappointment, could this study prove the impetus that turns Chantix's fortune around?
Shareholders of Genworth Financial headed for the hills after its weaker-than-expected second-quarter results. Is there any hope for a rebound?
Keeping an eye on what big investors are doing can deliver insights and investment ideas.
Are DPP-4 inhibitors like Januvia on their way out? A new long-term study from partners Eli Lilly and Boehringer Ingelheim suggests it's a possibility.
Keeping an eye on what the smart investors are doing can pay off.
GlaxoSmithKline and Novartis get together for another potential blockbuster deal.
Forget sulking! You should welcome last week's stock market correction with open arms, as it gives you an opportunity to buy some high-quality companies on the cheap.
Big changes are coming to the banking sector according to this new study, and these changes will be critical to lowering costs and luring in the next generation of banking customers.